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The current South African Department of Health guideline on
when to initiate highly active antiretroviral therapy (HAART) in
adults is based on the 2002 WHO guidelines. It is a very
conservative guideline, with HAART being initiated with AIDS,
diagnosed either clinically (World Health Organization (WHO)
stage 4) or immunologically (CD4+ lymphocyte count < 200
cells/µl). The current Southern African HIV Clinicians Society
guidelines extend these conservative guidelines to include
patients with other evidence of clinical immune suppression
(WHO clinical stage 3) and patients with CD4 counts 200 - 350
cells/µl. In common with international guidelines, it is
recommended that patients in the CD4 stratum 200 - 350
cells/µl be followed up until their CD4 count is close to 200
cells/µl, unless their viral load is high. I shall centre my
argument on the proposal to use the SA HIV Clinicians Society
guidelines to initiate HAART in the public sector.
The evidence that starting HAART at CD4 counts 200 - 350
cells/µl leads to a better outcome than at counts < 200 cells/µl
is persuasive rather than definitive as it comes from
observational cohort studies, not randomised controlled trials.
These cohort studies show worse short-term (generally 3
years) survival in patients commencing HAART at counts
< 200 cells/µl. The magnitude of this benefit is less impressive
when controlled for lead time,1 which is a source of bias in
cohort studies. Nevertheless, the survival benefit remains even
after correcting for lead time. The key issue though is that the
survival benefit is over the short term. 
As argued by Philips et al.,2 HAART is a long-term intervention.
We do not yet know how long HAART will prolong survival, but
it is unlikely that the average patient will have normal survival.
We know that there is a steady failure rate on HAART, and that
achieving virological success (an undetectable viral load) is
progressively more difficult with successive regimens, largely
owing to resistance. Although there is clinical benefit in
continuing HAART despite resistance, ultimately HIV disease
progression does occur.3 Taking a longer time view of HAART,
Philips et al. concluded that it is ‘likely that those deferring
ART [until CD4 counts < 200 cells/µl] ... eventually will
experience somewhat lower long-term risk of AIDS and death
than if they had started ART immediately’, because most
patients will eventually fail therapy. Therefore I do not believe
there is a compelling case to be made for moving the CD4
count criterion for starting HAART in the public sector.
Starting at WHO stage 3 is attractive for resource-poor
countries, particularly for those without access to flow
cytometry for CD4+ lymphocyte count monitoring. Clinical
staging is simple to learn for nurse-driven services.
Furthermore, it is known that WHO stage 3 confers a relatively
poor survival independently of the CD4 count. However, when
facilities to monitor CD4 counts exist, these should be used in
conjunction with WHO staging. Tuberculosis occurs across a
wide spectrum of immunity in HIV infection. In our study of
incident cases of tuberculosis, about a third of cases presented
with CD4 counts > 500 cells/µl.4 I do not believe that these
patients need HAART. A further problem is that oral thrush, a
common stage 3 condition, can occur with seroconversion or
following a course of antibiotics. The 2003 revision of the
WHO guidelines of when to initiate HAART in resource-poor
settings has added WHO 3 together with CD4 count < 350
cells/µl for those countries, like South Africa, which can
measure CD4 counts. Although I do believe we should consider
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adding this to our public sector guideline in the future, I do
not believe we should add it soon.
South Africa has a massive burden of HIV infection. Adding
WHO stage 3 to the criteria of when to start HAART will
approximately treble the number of eligible patients. Even if
we only targeted stage 4 patients (without using CD4 criteria)
and only managed to treat 50% of these, we would still need
to treat approximately 1 400 000 by 2008 (extrapolated from
ASSA 2002 model by Andrew Boulle). Until it is clear that we
can achieve this daunting target we should not talk about
easing the criteria for initiation. We have an obligation to first
deal with those who are suffering most.
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ANTIRETROVIRAL PROGRAMME RATIONALES
Antiretroviral therapy (ART) programmes are a part of the
response to the massive mortality occurring in the countries
most affected by the HIV epidemic. UNAIDS estimated that 2.3
million deaths from AIDS occurred in sub-Saharan Africa
during 2004. South Africa faces the prospect of an
accumulated 6 - 7 million AIDS deaths by 2010, with the
majority affecting the age group 20 - 40 years, a stage of life
when adults are productive and caring for the next
generation. In September 2003 the World Health Organization
(WHO) declared the lack of access to HIV treatment a global
health emergency. WHO called for ‘unprecedented action’ to
ensure that by the end of 2005 at least 3 million people in
need of ART will have access to it. To date the national
evaluations of the status of ART programmes have revolved
around reporting on numbers on treatment rather than
impact on AIDS mortality. The primary purpose of the South
African and other national ARV programmes is to minimise
HIV-associated mortality.  
DEBATE FOCUS
The key to the present debate revolves around the thresholds
of ART initiation as set out in various treatment guidelines and
how different programme entry criteria impact on population
HIV-related deaths. The WHO Treatment Guidelines Committee
recognises in the 2003 guidelines preface that they will need
to be updated on a regular basis in order to reflect ‘best
current clinical practice’. The SA national rollout programme
currently uses the older WHO 2000 guidelines, which are not
internationally recognised as the ‘best current clinical practice’
and have ceased to be used by many other countries in our
region such as Botswana, Namibia and Uganda.
The current SA guidelines recommend both clinical and CD4
criteria for allowing access to the ART programme. 
APPRAISAL OF PRESENT SA GUIDELINES
Firstly the clinical and CD4 count criteria are very mismatched.
Patients with AIDS die at a rate of 6% per month while
asymptomatic patients with CD4 counts < 200 µl have
approximately a 1% monthly mortality. Clinical AIDS is
therefore very specific for identifying patients at high risk of
death while a CD4 of < 200 is very sensitive measure.
Secondly, the majority of patients access health care and
antiretroviral (ARV) programmes because they have clinical
symptoms rather than because they have just passed the CD4
threshold of < 200 cells. The median CD4 cell count of patients
accessing ARVs in Kampala, Uganda, is still 65/µl and in
Gugulethu, Cape Town, it is less than 100/µl after 3 years of
the programme. A CD4 count of < 200 cells/µl will gain utility
when a large proportion of people living with AIDS (PWAs)
have access to sequential CD4 count monitoring. This CD4
count threshold would then be a very sensitive but not specific
measure for identifying patients at high risk of death.
However, widespread CD4 count testing is not widely available
in South Africa or elsewhere in sub-Saharan Africa. Thirdly, the
clinical threshold of AIDS as an entry criterion for ART results
in high mortality, as there are inevitable delays in accessing
treatment. In Gugulethu the time between referral and
commencing ARVs is short at 28 days. However, 66% of
programme deaths are recorded during this period, occurring
almost exclusively in those patients with AIDS before they
could start ARVs. The reported delay in the Médecins Sans
Frontières, Khayelitsha, ARV project was 4 months. Waiting
time to access ARVs in other programmes is frequently much
longer. Waiting lists in Cape Town hospitals have been up to 8
months and are in excess of 8 months in Malawi, which results
in an unrecorded 50% of AIDS patients dying before access to
ARV programmes. Currently this pre-treatment mortality is
not recorded as part of the treatment programme, although
reduction of HIV mortality is the primary aim of ARV
treatment. AIDS patients not only have a high in-programme
death rate, they are also difficult to clinically manage and
investigate, thereby consuming a disproportionate amount of
programme resources. AIDS is therefore too late a threshold
for entry into an ARV programme. 
If the guidelines do not represent ‘best current clinical
practice’ but are being used as a means of rationing access to
care, they should identify those who will benefit most from
therapy.  Clinical stage is more predictive of HIV mortality than
CD4 count. South African published data have reported that
the death rate of patients with WHO stage 3 disease is 2 - 2.5
times higher than that of asymptomatic patients with < 200
CD4 cells/µl. Until CD4 count testing is more widely available,
